|

Fulvestrant Clinical Trials

67 actively recruiting trials across 29 locations

▲ +1 trial since May 2026

Also known as: Experimental group, FASLODEX®, Faslodex, Faslodex(ICI 182,780), Faslodex, +10 more

Pipeline

Phase 1: 18Phase 2: 22Phase 3: 9Phase 1/2: 16

Top Sponsors

Hoffmann-La Roche5
Novartis Pharmaceuticals4
Pfizer3
BeOne Medicines3
Relay Therapeutics, Inc.2

Indications

Cancer67
Breast Cancer60
Metastatic Breast Cancer18
Advanced Breast Cancer12
Hormone Receptor Positive Breast Cancer7

Other13 trials

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Phase 2

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

Phase 1/2

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

N/A

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Phase 3

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy

Phase 2

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Phase 2

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Phase 3

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Phase 2

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Phase 2

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Phase 2

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

Phase 1

Los Angeles, California10 trials

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site

Phase 1/2

SNV4818 in Participants With Advanced Solid Tumors

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

Phase 1/2

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

START Los Angeles

Phase 1/2

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

START Los Angeles

Phase 1/2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

University of California LA

Phase 1/2

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

University of Southern California

Phase 1/2

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

The START Center for Cancer Research

Phase 1

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Los Angeles Cancer Network

Phase 2

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

UCLA Jonsson Comp Cancer Center

Phase 1

Birmingham, Alabama4 trials

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

University of Alabama At Birmingham Hospital

Phase 1

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

University of Alabama at Birmingham

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Tucson, Arizona4 trials

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Research Site

Phase 3

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

University of Arizona Cancer Center

Phase 2

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

The University of Arizona Cancer Center

Phase 1

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site

Phase 3

Duarte, California4 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

City of Hope Comprehensive Cancer Center

Phase 1

Study of INCB123667 in Subjects With Advanced Solid Tumors

City of Hope Medical Center

Phase 1

Gilbert, Arizona3 trials

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

Banner MD Anderson Cancer Center

Phase 1/2

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Banner MD Anderson Cancer Center

Phase 3

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Anchorage, Alaska2 trials

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Alaska Womens Cancer Care ( Site 0037)

Phase 2

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Alaska Oncology and Hematology

Phase 3

Newport Beach, California2 trials

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Hoag Memorial Presbyterian

Phase 1

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

Hoag Memorial Presbyterian

Phase 1

New Haven, Connecticut2 trials

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Yale School of Medicine

Phase 1/2

Study of AVZO-021 in Patients With Advanced Solid Tumors

Yale Cancer Center

Phase 1/2

Chicago, Illinois2 trials

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Northwestern Memorial Hospital

Phase 1

Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

University of Chicago Medicine Comprehensive Cancer Center

Phase 1

St Louis, Missouri2 trials

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Washington University School of Medicine

Phase 2

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Siteman Cancer Center at Washington University

Phase 2

Daphne, Alabama1 trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Southern Cancer Center

Phase 3

Chandler, Arizona1 trial

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Ironwood Cancer & Research Centers

Phase 3

Goodyear, Arizona1 trial

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

City of Hope - Phoenix ( Site 0006)

Phase 2

Scottsdale, Arizona1 trial

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

HonorHealth

Phase 2

Encinitas, California1 trial

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

California Cancer Associates for Research and Excellence

Phase 1

La Jolla, California1 trial

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

UC San Diego Moores Cancer Center

Phase 1

Orange, California1 trial

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2

Denver, Colorado1 trial

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sarah Cannon Research Institute (Scri) At Health One

Phase 1

Orlando, Florida1 trial

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Florida Cancer Specialists

Phase 1/2

Sarasota, Florida1 trial

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Florida Cancer Specialists

Phase 1

Tampa, Florida1 trial

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Moffitt Cancer Center

Phase 2

Boston, Massachusetts1 trial

VS-6766+Abema+Fulv in Met HR+/HER- BC

Massachusetts General Hospital Cancer Center

Phase 1/2

Marshall, Minnesota1 trial

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Avera Cancer Institute - Marshall

Phase 2

Rochester, Minnesota1 trial

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

Biotheryx Investigative Site

Phase 1

Lebanon, New Hampshire1 trial

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Dartmouth Hitchcock Medical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1/2

Cleveland, Ohio1 trial

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Phase 2

Oklahoma City, Oklahoma1 trial

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

OU Health Stephenson Cancer Center

Phase 2

Nashville, Tennessee1 trial

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Tennessee Oncology PLLC

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.